Martine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $517.28, for a total transaction of $4,914,160.00. Following the completion of the transaction, the chief executive officer owned 324,443 shares of the company’s stock, valued at approximately $167,827,875.04. The trade was a 2.84% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

United Therapeutics Price Performance

NASDAQ UTHR traded up $11.23 during trading hours on Thursday, reaching $527.91. 391,005 shares of the company’s stock traded hands, compared to its average volume of 490,061. United Therapeutics Corporation has a 52-week low of $302.19 and a 52-week high of $609.35. The firm has a 50-day simple moving average of $531.06 and a 200 day simple moving average of $538.56. The firm has a market cap of $22.64 billion, a PE ratio of 18.89, a PEG ratio of 1.76 and a beta of 0.59.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, topping analysts’ consensus estimates of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The business had revenue of $783.30 million for the quarter, compared to analysts’ expectations of $804.65 million. During the same quarter in the prior year, the company earned $6.41 earnings per share. The business’s revenue was down 1.9% compared to the same quarter last year. Sell-side analysts forecast that United Therapeutics Corporation will post 26.33 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently weighed in on UTHR. Bank of America reduced their price target on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a research report on Friday, July 10th. JPMorgan Chase & Co. increased their target price on United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a research note on Thursday, July 23rd. Royal Bank Of Canada reduced their target price on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating for the company in a report on Thursday, August 6th. Wells Fargo & Company upgraded United Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $575.00 to $735.00 in a research note on Thursday, May 7th. Finally, Weiss Ratings raised United Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a report on Thursday, August 13th. Eleven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $646.00.

Institutional Trading of United Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Amundi boosted its stake in United Therapeutics by 48.4% in the 2nd quarter. Amundi now owns 219,094 shares of the biotechnology company’s stock worth $118,712,000 after purchasing an additional 71,495 shares during the period. California State Teachers Retirement System grew its holdings in United Therapeutics by 55,526.2% during the 2nd quarter. California State Teachers Retirement System now owns 33,288,952 shares of the biotechnology company’s stock valued at $18,036,953,000 after buying an additional 33,229,108 shares in the last quarter. Wedmont Private Capital raised its position in shares of United Therapeutics by 4.9% during the second quarter. Wedmont Private Capital now owns 1,751 shares of the biotechnology company’s stock valued at $958,000 after buying an additional 82 shares during the last quarter. Saudi Central Bank raised its position in shares of United Therapeutics by 82.8% during the second quarter. Saudi Central Bank now owns 2,761 shares of the biotechnology company’s stock valued at $1,496,000 after buying an additional 1,251 shares during the last quarter. Finally, AlphaGrep UK Ltd purchased a new position in shares of United Therapeutics during the second quarter valued at approximately $836,000. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.